US20030166037A1 - Aggrecanase-1 and -2 peptide substrates and methods - Google Patents

Aggrecanase-1 and -2 peptide substrates and methods Download PDF

Info

Publication number
US20030166037A1
US20030166037A1 US10/050,200 US5020002A US2003166037A1 US 20030166037 A1 US20030166037 A1 US 20030166037A1 US 5020002 A US5020002 A US 5020002A US 2003166037 A1 US2003166037 A1 US 2003166037A1
Authority
US
United States
Prior art keywords
peptide
aggrecanase
leu
seq
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/050,200
Other languages
English (en)
Inventor
Anne Fourie
Lars Karlsson
Fawn Coles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Priority to US10/050,200 priority Critical patent/US20030166037A1/en
Assigned to ORTHO-MCNEIL PHARMACEUTICAL, INC. reassignment ORTHO-MCNEIL PHARMACEUTICAL, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COLES, FAWN, FOURIE, ANNE, KARLSSON, LARS
Priority to PCT/US2003/001327 priority patent/WO2003062263A2/fr
Priority to AT03702145T priority patent/ATE458810T1/de
Priority to CA2473513A priority patent/CA2473513C/fr
Priority to DE60331414T priority patent/DE60331414D1/de
Priority to EP03702145A priority patent/EP1474509B1/fr
Priority to ES03702145T priority patent/ES2339758T3/es
Priority to AU2003203028A priority patent/AU2003203028A1/en
Publication of US20030166037A1 publication Critical patent/US20030166037A1/en
Priority to US11/012,797 priority patent/US7312045B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals

Definitions

  • the present invention describes synthetic peptide substrates of the metalloproteases, aggrecanase-1 and/or -2, suitable for use in assays of enzyme activity.
  • the invention also describes methods using these peptides to discover pharmaceutical agents that modulate these proteases.
  • the disintegrin metalloprotease (or ADAM) family of cell surface proteolytic enzymes is known to play roles in sperm-egg binding and fusion, muscle cell fusion, neurogenesis, modulation of Notch receptor and ligand processing, and processing of the pro-inflammatory cytokine, TNF ⁇ (Primakoff and Myles, Trends Genet 16:83-87, 2000).
  • the ADAMs have been shown to consist of pre-, pro-, protease, disintegrin-like-, cysteine-rich, epidermal growth factor-like, transmembrane, and cytoplasmic domains.
  • ADAMTS proteins Members of a novel sub-family of the ADAMs, the ADAMTS proteins, lack the transmembrane domain and contain unique thrombospondin motifs, believed to mediate their binding to the extracellular matrix (Tang and Hong, FEBS Lett. 445:223-225, 1999).
  • Aggrecan is the major proteoglycan of cartilage (Abbaszade et al., J. Biol. Chem. 274:23443-23450, 1999; Tortorella et al., Science 284:1664-1666, 1999).
  • Aggrecanase-1 and -2 are able to cleave aggrecan at this site.
  • a 40 amino acid peptide representing the sequence of aggrecan surrounding the aggrecanase cleavage site (PCT Publication Number WO 00/05256) was able to serve as a substrate for aggrecanase enzymatic activity; however, no peptides less than 40 amino acids in length functioned as suitable substrates for aggrecanase activity, suggesting that shorter substrates, such as substrates of 20 amino acids in length, would not work.
  • a sensitive and specific assay for the aggregan degrading metalloproteases would be helpful in identifying inhibitors of these enzymes for potential therapeutic agents against cartilage damage associated with osteoarthritis and inflammatory joint disease.
  • This invention relates to amino acid peptides shorter than 40 amino acids, unrelated to the aggrecan sequence, but containing aggrecanase sensitive sites, and their use in assays suitable for HTS formats.
  • the present invention relates to peptides less than 40 amino acids in length having a cleavage site between a glutamic acid on the N-terminal side of the cleavage site and a non-polar or uncharged residue on the C-terminal side of the cleavage site and wherein the peptide is cleavable by an enzyme having an amino acid sequence of SEQ ID NO:8 (Aggrecanase-1) and/or SEQ ID NO:9 (Aggrecanase-2).
  • the peptide comprises the amino acid sequence of SEQ ID NO:3 and SEQ ID NO:4.
  • the peptide is of natural or synthetic origin.
  • the peptide comprises a detectable label selected from the group consisting of 125 I, 131 I, 3 H, 14 C, 35 S, 32 P, 33 P, a fluorescent dye, or a colorimetric indicator.
  • the peptide preferably also comprises a fluorophore and a quencher or acceptor located at opposite ends of the cleavage site of the peptide.
  • the peptide further comprises an affinity moiety located at opposite ends of the cleavage site of the peptide.
  • the invention relates to a method to identify a compound that inhibits Aggrecanase enzymatic activity comprising the steps of: contacting a test compound, an Aggrecanase, and a peptide less than 40 amino acids in length wherein the peptide comprises a cleavage site between a glutamic acid on the N-terminal side of the cleavage site and a non-polar or uncharged amino acid residue on the C-terminal side of the cleavage site and wherein the peptide is cleavable by an enzyme having the amino acid sequence of SEQ ID NO:8.; and detecting cleavage of the peptide, wherein inhibition of peptide cleavage in the presence of a test compound indicates compound inhibition of Aggrecanase enzymatic activity.
  • the method is performed in a single reaction vessel.
  • the enzyme is selected from the group consisting of Aggrecanase-1 or Aggrecanase-2.
  • the peptide is selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 5, SEQ ID NO:6 and SEQ ID NO:7.
  • the peptide further comprises a detectable label selected from the group consisting of 125 I, 131 I, 3 H, 14 C, 35 S, 32 P, 33 P, a fluorescent dye, or a colorimetric indicator.
  • the peptide preferably further comprises a fluorophore and a quencher or acceptor located at opposite ends of the cleavage site of the peptide.
  • the contacting step further comprises a cell expressing the Aggrecanase.
  • the invention in another aspect of this invention, relates to a method to detect the ability of a compound to inhibit Aggrecanase-1 or -2 enzymatic activity comprising the steps of: contacting a test compound, an Aggrecanase secreted by a cell, and a peptide having an amino acid sequence selected from the group consisting of SEQ.ID.NO.:3 or SEQ.ID.NO.:4; incubating the compound, enzyme, and peptide to permit enzymatic cleavage of the peptide; and measuring enzymatic cleavage of the peptide wherein the method is conducted in a single reaction vessel without further manipulation.
  • the peptide comprises a detectable label selected from the group consisting of 125 I, 131 I, 3 H, 14 C, 35 S, 32 P, 33 P, a fluorescent dye, or a calorimetric indicator.
  • the peptide comprises a fluorophore and a quencher or acceptor located at opposite ends of the cleavage site of the peptide.
  • the invention relates to a method to identify a compound capable of inhibiting Aggrecanase activity comprising the steps; providing a peptide comprising an affinity moiety, an amino acid sequence selected from a group consisting of SEQ.ID.NO.:3 SEQ.ID.NO.:4 and a detectable label, said affinity moiety and label located on opposite sides of a cleavage site encoded by the amino acid sequence; contacting the peptide with an affinity capture coated solid phase support for sufficient time to bind a portion of the peptide; washing the support to remove unbound peptide; contacting a solution comprising a test compound and functional enzyme with the peptide bound solid phase support for sufficient time to allow enzymatic cleavage of the peptide, thereby releasing the peptide and detectable label into the solution; and measuring changes in the quantity of the detectable label as a result of compound modulation of expected enzymatic function.
  • the enzyme is selected from the group consisting of Aggrecanase-1 and -2.
  • the peptide comprises a detectable label selected from the group consisting of 125 I, 131 I, 3 H, 14 C, 35 S, 32 P, 33 P, a fluorescent dye, or a colorimetric indicator.
  • FIG. 1 illustrates the domain structures of (A) full-length Aggrecanase-1 protein, (B) full-length Aggrecanase-2 protein and (C) the recombinant truncated forms used in a preferred protease assay of this invention.
  • FIG. 2 illustrates the relative activities of Aggrecanase-1(A) and -2 (B) for 56 different FRET peptides, A1 to H7. In FIG. 2, every other peptide is numbered.
  • FIG. 3 provides the kinetic analysis of the relative affinities of Aggrecanase-2 for cleavage of 2 different peptides
  • FIG. 4 illustrates the use of the Aggrecanase-1 and -2 peptide cleavage assays to identify inhibitory compounds.
  • FIG. 4A is a comparison of inhibition of Aggrecanase-1 proteolytic activity by compounds A and B.
  • FIG. 4B provides the IC50 analysis for inhibition of Aggrecanase-2 by inhibitory compounds, A, B and C.
  • the invention relates to peptide substrates useful to measure the enzymatic activity of Aggrecanase-1 and/or -2 metalloproteases.
  • peptide substrates identified in this invention it is possible to find others that are capable of being cleaved by the preferred truncated Aggrecanase-1 and -2 enzymes of this invention.
  • Preferred recombinant truncated forms of human Aggrecanase-1 and -2 i.e., Aggrecanase lacking some portion of the complete native sequence
  • this invention were creating using the pro- and protease domains and optionally included a FLAG epitope tag, as provided in schematic in FIG.
  • the invention also relates to assays using the peptides of this invention to detect compounds that inhibit Aggrecanase enzymatic activity.
  • the assay is a homogeneous in vitro protein-based assay to detect compound modulation of Aggrecanase-1 and/or -2 enzymatic activity.
  • the term “homogeneous” refers to an assay conducted in a single vessel where there is no further reagent manipulation after the reaction reagents are placed in a vessel.
  • a preferred method comprises the steps of;
  • the detecting step comprises detecting a change in the level of substrate cleavage.
  • the change in the level of substrate cleavage is compared to the change in the level of substrate cleavage in a reaction vessel containing Aggrecanase and peptide substrate in the presence of a control test compound that has a known capacity or no capacity to inhibit Aggrecanase activity or alternatively in a reaction vessel without test compound.
  • the peptide substrate is selected from SEQ ID NO:3 (E5 in FIG. 2) or SEQ ID NO:4 (G7 in FIG. 2).
  • peptides substrates in the assays of this invention for Aggrecanase-2 include, but are not limited to: ID from SEQ Sequence ID NO G1 Aedans-EKARVLAEAADabcyl-Kamide 5 B3 Aedans-EKARVLAEAMDabcyl-Kamide 6 C7 Aedans-ERABQQRLKSQDLDabcyl-Kamide 7
  • peptides tested are provided in Table II.
  • a variety of peptides can also serve as substrates for Aggrecanase-1 and/or -2 activity.
  • the present set of peptide substrates was selected by identifying other protease substrates known in the art.
  • the peptides included a collection of substrates for other proteases, as well as a number of sequences corresponding to membrane proximal cleavage sites of various proteins postulated to be released by metalloproteases (including those published by Roghani et al., J. Biol. Chem. 274:3531-340, 1999) for ADAM9/MDC9).
  • metalloproteases including those published by Roghani et al., J. Biol. Chem. 274:3531-340, 1999
  • Aggrecanase refers to a truncated enzyme (as shown in FIG. 1) that displays enzymatic cleavage of a peptide substrate, and for which the corresponding full-length enzyme is known to have the capacity to cleave aggrecan. Efficient cleavage of aggrecan depends on multiple interactions between the enzyme and aggrecan. For example, cleavage depends on an intact N-terminal portion of the substrate, aggrecan (Horber et al., Matrix Biology 19:533-543, 2000). Tortorella et al. ( J. Biol. Chem.
  • Nucleic acid encoding the truncated versions of these enzymes used in the assays of this invention are provided here as SEQ ID NOS:1 and 2, corresponding to truncated Aggrecanase-1 and truncated Aggrecanase-2, respectively.
  • Aggrecanases used in this invention are truncated forms of a full length native Aggrecanase provided by the GenBank citations above, other Aggrecanases can be used in this invention as long as they retain their ability to cleave exemplarly peptides SEQ ID NO:3 and SEQ ID NO:4.
  • the Aggrecanases used in this invention can be full length, partial, truncated, chimeric or modified enzymes that still retain their ability to cleave the peptides as described in this invention.
  • Aggrecanase cleavage sites in aggrecan contain glutamic acid on the N-terminal side of the cleavage site (P1 position) and a non-polar or uncharged residue on the C-terminal side of the cleavage site (P1′ position), namely alanine, leucine or glycine (Caterson et al., Matrix Biology 19:333-344, 2000; Tortorella et al., J. Biol. Chem. 275 18566).
  • the truncated Aggrecanase-2 used in the assays described here cleaves the peptides of SEQ ID NOS: 3 and 4 between glutamic acid and leucine residues, consistent with the cleavage specificity of aggrecan cleavage sites.
  • the term “compound” is used herein in connection with a small molecule, preferably an organic molecule that has the potential to disrupt the specific enzymatic activity of the enzyme.
  • compounds may include small organics, synthetic or natural amino acid peptides, proteins, synthetic or natural nucleic acid sequences, or any chemical derivatives of the aforementioned.
  • chemical derivative describes a molecule that contains additional chemical moieties that are not normally a part of the base molecule. Such moieties may improve the solubility, half-life, absorption, etc. of the base molecule. Alternatively the moieties may attenuate undesirable side effects of the base molecule or decrease the toxicity of the base molecule. Examples of such moieties are described in a variety of texts, such as Remington: The Science and Practice of Pharmacy. 1995. Mack Publishing Co. ISBN 0912734051.
  • the methods described herein are especially useful for high throughput screening (HTS) of compounds to discover compounds that modulate Aggrecanase function.
  • high throughput refers to an assay design that allows easy analysis of multiple samples simultaneously, and capacity for robotic manipulation.
  • Preferred assays are homogeneous assays.
  • Preferred assays also include assay designs that are optimized to reduce reagent usage in order to achieve the analysis desired.
  • the methods described herein demonstrate highly robust performance and good linearity as a function of enzyme concentration and substrate concentration. For example in the assays of the present invention, at appropriately adjusted enzyme and substrate concentrations, the assay was linear for up to four hours. From FIG.
  • Examples of assay formats include 96-well or 384-well plates, levitating droplets, and “lab on a chip” microchannel chips used for liquid handling experiments.
  • capillary electrophoresis (CE)-based assays for the activity of proteases have been developed.
  • the assays can be carried out in small volumes ( ⁇ 51 ⁇ l).
  • both the fluorescent-labeled substrate and product can be monitored by laser-induced fluorescence, based on the ability of CE to rapidly separate the two species.
  • the present invention provides a homogeneous in vitro cell-based method to detect compound modulation of Aggrecanase enzymatic activity.
  • the cells express Aggrecanase and the peptide substrate and test compound are in contact with Aggrecanase. Aggrecanase is preferably released extracellularly.
  • the Aggrecanase is an Aggrecanase 1 or an Aggrecanase 2. The method comprises the steps of:
  • the assays of this invention could be made non-homogeneous. That is, the assay could be modified to require more than one vessel or a wash step requiring that all events to do not take place in a single reaction sample.
  • Such assays can involve, for example, the immobilization of the substrate peptide.
  • an affinity moiety-affinity capture pair such as streptavidin capture of a biotinylated substrate peptide.
  • Affinity capture pairs are well known in the art and include, for example, avidin/biotin, antibody capture of a region of the substrate peptide, and polyhistidine/immobilized nickel.
  • a preferred non-homogeneous method comprises the steps of:
  • the Aggrecanase is Aggrecanase 1 and/or 2.
  • the solution is transferred to a reaction vessel prior to the measuring step.
  • solid phase support, affinity capture, unbound versus bound peptide, and the like are all well-known terms to those of ordinary skill in the art to who this invention pertains and therefore these definitions will not be repeated here.
  • a change in the quantity of product can be expressed as the total amount of product changing over time (a stop-time assay) or can be kinetic where a change in the enzymatic rate is measured as a function of time.
  • Kinetic assays are preferably measured from the time of initial contact of the enzyme and substrate to a point in time where approximately 50% of the maximum observed product are generated.
  • the amount of expected Aggrecanase enzymatic activity can be determined by running, concurrently or separately, an assay using a compound that does not inhibit enzymatic function (i.e., a blank or a control compound), or with a solvent vehicle that has similar properties as that used for the test compound but lacks any test compound, such as DMSO, DMF, or isopropyl alcohol.
  • a compound that does not inhibit enzymatic function i.e., a blank or a control compound
  • a solvent vehicle that has similar properties as that used for the test compound but lacks any test compound, such as DMSO, DMF, or isopropyl alcohol.
  • the amount of time necessary for cellular contact with the compound is empirically determined, for example, by running a time course with a known Aggrecanase modulator and measuring change as a function of time.
  • Cells useful in the cell-based Aggrecanase assays of this invention are those cells that naturally express Aggrecanase, or cells transfected with recombinant Aggrecanase. These cells may be immortalized cell lines or primary culture cells from any mammal, preferably murine, rat, rabbit, monkey, chimpanzee, or human.
  • Methods for detecting compounds that modulate Aggrecanase proteolytic activity comprise combining a test compound with an Aggrecanase protein and a suitable labeled substrate and detecting the ability of the enzyme to cleave the substrate in the presence of the compound. Enzymatic cleavage can result in release of the label or release of a labeled peptide fragment that can be distinguished from intact labeled peptide.
  • the substrate is labeled.
  • a variety of methods for exploiting labeled substrates are known in the art. Examples of different types of labeled substrates include, for example, substrate that is radiolabeled (Coolican et al., J. Biol. Chem.
  • Radioisotopes useful in the present invention include those well known in the art, specifically 125 I, 131 I, 3 H, 14 C, 35 S, 32 P, and 33 P Radioisotopes are introduced into the peptide by conventional means, such as iodination of a tyrosine residue, phosphorylation of a serine or threonine residue, or incorporation of tritium, carbon or sulfur utilizing radioactive amino acid precursors.
  • Fluorescent resonance energy transfer (FRET)-based methods can also be used to detect compounds that modulate Aggrecanase proteolytic activity.
  • FRET Fluorescent resonance energy transfer
  • Compounds that are activators will increase the rate of substrate degradation resulting in a reduction in substrate as a function of time.
  • Compounds that are inhibitors will decrease the rate of substrate degradation and will result in greater remaining substrate as a function of time.
  • a preferred assay format useful for the method of the present invention is a FRET-based method using peptide substrates that contain a fluorescent donor with either a quencher or acceptor that are separated by a peptide sequence encoding the Aggrecanase cleavage site.
  • a fluorescent donor is a fluorogenic compound that can absorb energy and transfers a portion of the energy to another compound.
  • fluorescent donors suitable for use in the present invention include, but are not limited to, coumarins, xanthene dyes such as fluoresceines, rhodols, and rhodamines, resorufins, cyanine dyes bimanes, acridines, isoindols, dansyl dyes, aminophthalic hydrazides such as luminol and isoluminol derivatives, aminonapthalimides, aminobenzofurans, aminoquinolines, dicanohydroquinones, and europium and terbium complexes and related compounds.
  • a quencher is a compound that reduces the emission from the fluorescent donor when it is appropriately proximally located to the donor.
  • Preferred quenchers do not generally re-emit the energy in the form of fluorescence.
  • quenching moieties include indigos, benzoquinones, anthraquinones, azo compounds, nitro compounds, indoanilines, and di- and triphenylmethanes.
  • a FRET method using a donor/quencher pair measures increased emission from the fluorescent donor as a function of Aggrecanase enzymatic activity upon the peptide substrate. Therefore a test compound that antagonizes Aggrecanase will generate an emission signal between two control samples—a low (basal) fluorescence from the FRET peptide alone and a higher fluorescence from the FRET peptide digested by the activity of enzymatically active Aggrecanase.
  • An acceptor is a fluorescent molecule that absorbs energy from the fluorescent donor and re-emits a portion of the energy as fluorescence.
  • An acceptor is a specific type of quencher that enables a separate mechanism to measure Aggrecanase proteolytic efficacy.
  • Methods that use a donor/acceptor pair measure a decrease in acceptor emission as a function of Aggrecanase enzymatic activity upon the peptide substrate. Therefore a test compound that antagonizes Aggrecanase will generate an emission signal between two control samples—a higher basal fluorescence from the FRET peptide alone and a lower fluorescence from the FRET peptide digested by the activity of enzymatically active Aggrecanase.
  • acceptors useful in the methods of the present invention include, but are not limited to, coumarins, fluoresceins, rhodols, rhodamines, resorufins, cyanines, difluoroboradiazindacenes, and phthalcyanines.
  • FRET peptides can also be used for zymography (see PCT publication number WO 01/94377 to Fourie et al.) following SDS polyacrylamide gel electrophoresis.
  • Aggrecanase proteins usually comprise: an N-terminal pro-domain and a metalloprotease domain, followed by the disintegrin domain, cysteine-rich domain, epidermal growth factor repeat, thrombospondin repeats and a spacer region, as illustrated in FIG. 1.
  • ADAMTS proteins Aggrecanase-1 and -2
  • PCR products containing the pro- and protease domains and a C-terminal FLAG epitope (used for immuno-detection and purification) were cloned into pFastBac1 (GibcoBRL) vectors using standard techniques.
  • the DNA sequences of truncated Aggrecanase 1 and 2 used in the methods of this invention are provided as SEQ ID NOS:1 and 2 respectively.
  • the protein sequences corresponding to these DNA sequences are provided as SEQ ID NOS: 8 and 9.
  • Recombinant baculovirus for truncated Aggrecanase-1 or -2 expression was generated from the pFastBac1 construct described above using the Bac-to-Bac system (Gibco BRL). Sf9 cells were infected with baculovirus and the medium was collected after 72 hours. The medium was concentrated 10-fold by ultrafiltration, and exchanged to TBS (Tris Buffered Saline) by repeated addition and re-concentration. The supernatant was centrifuged for one hour at 15000 ⁇ g, filtered through a 0.45 ⁇ M filter to remove debris, and incubated, with mixing, overnight at 4° C. with M2- ⁇ Flag-agarose (Sigma).
  • the resin was loaded into a column and washed with TBS, followed by elution of the bound material with 0.1M Glycine (pH 3.5) and immediate neutralization by addition of 12.5 ⁇ l/ml of 2M Tris-HCl, pH 8.
  • the supernatant from the infection (before and after incubation with M2- ⁇ Flag-agarose) and fractions from the purification were analyzed by SDS-PAGE followed by staining and Western blotting.
  • SDS-PAGE fractions containing the immunopurified Aggrecanase-1 or -2 protein contained a protein band with an apparent molecular weight of about 30 kDa.
  • Fifty-six different peptides were synthesized to test for protease activity (see Table 3 below).
  • the peptides included a collection of substrates for other proteases, as well as a number of sequences corresponding to membrane proximal cleavage sites of various proteins postulated to be released by metalloproteases (including those published by (Roghani et al., J. Biol. Chem. 274:3531-340, 1999) for ADAM9/MDC9).
  • metalloproteases including those published by (Roghani et al., J. Biol. Chem. 274:3531-340, 1999) for ADAM9/MDC9
  • FRET fluorescence resonance energy transfer
  • cleavage of the peptides were monitored by the increase in Aedans fluorescence at 460 nm (excitation 360 nm) as a result of the decrease in proximity of the Dabcyl quencher.
  • the assay was performed by diluting the Aggrecanase-1 (approximately 2.5 to 5 ⁇ g of protein, 85 to 167 picomoles, SEQ ID NO:8) or Aggrecanase-2 (approximately 0.5 to 1 ⁇ g of protein, 17 to 33 picomoles, SEQ ID NO:9), in assay buffer (50 mM HEPES pH 7.5, 10 mM CaCl 2 , 0.1M NaCl and 0.05%(w/v) Brij-35 detergent (Sigma).
  • the reaction was initiated by the addition of peptide substrate to a final concentration of 100 uM for Aggrecanase-1 and 50 uM for Aggrecanase-2.
  • the assays were typically run for 60 minutes at room temperature and the slope of the kinetic increase in fluorescence was determined to calculate the rate of the reaction.
  • FIG. 2 illustrates the relative activities for the 56 different peptides, A1 to H7 (only every alternate peptide is numbered in FIG. 2) expressed in arbitrary, but relative units.
  • Aggrecanase-1 and -2 both showed the highest activity for peptide E5 (FasL1).
  • Aggrecanase-2 but not Aggrecanase-1, also showed high activity for cleavage of peptide G7 (29CD23).
  • Peptide D7 (16 amino acids) corresponds to the sequence within aggrecan containing the Glu373-Ala374 aggrecanase cleavage site.
  • Peptide E5 (SEQ ID NO:3) was also shown in similar screening assays to be a suitable substrate for the metalloproteases MMP7 and MMP 13 (Chemicon, Cat. #CC1059 and CC068 respectively).
  • Aggrecanase-2 was further analyzed for its rate of catalysis using 2 different peptides.
  • the assay was performed by diluting the Aggrecanase-2 in assay buffer (50 mM HEPES pH 7.5, 10 mM CaCl 2 , 0.1M NaCl and 0.05% Brij-35).
  • the reaction was initiated by the addition of substrate (FasL1 or 29CD23) to different final concentrations for analysis of affinities.
  • the assay was run for 60 minutes at room temperature.
  • FIG. 3 illustrates the proteolytic activity (in relative fluorescence units per minute) as a function of peptide concentration for peptides FasL1 and 29CD23.
  • the curves were fitted to the data with the program Grafit (Erithacus Software Lmited). The results of these analyses are provided in Table 2. The Vmax and Km for each substrate were calculated by non-linear fitting of the data.
  • the cleavage site for Aggrecanase-2 within each peptide was determined by LC-MS analysis to be between a glutamic acid and leucine residues in each case, as indicated in Table 2 by a carot within each peptide sequence.
  • Aggrecanase-1 (2.5 to 5 ⁇ g of protein, 85 to 167 picomoles) was diluted in assay buffer (50 mM HEPES pH 7.5, 10 mM CaCl 2 , 0.1M NaCl, 0.05% Brij-35). Samples were prepared containing putative inhibitors A (Chen et al. Biorg. Med. Chem. Lett. 6(13):1601-1606, 1996) or B (Bailey, et al. Biorg. Med. Chem. Lett. 9(21):3165-3170, 1999), shown below, at a final concentration of 7.5 micromolar.
  • the final %DMSO in the assay was 3% and it was determined experimentally that this concentration was not detrimental to the activity of the enzyme.
  • the reaction was initiated by the addition of FasL1 peptide substrate to a final concentration of 225 ⁇ M and readings were taken at one-minute intervals, for a total of 200 minutes at room temperature.
  • the assay was always performed at enzyme and substrate concentrations where the activity was linearly related to enzyme concentration and where the increase in fluorescence (reaction rate) was linear for at least the time of the assay. From FIG. 4A, it can be seen that for kinetic analysis, the signal-to-noise ratio is effectively infinite, as no change in the background (blank, no enzyme) is observed over the time of the assay. For endpoint measurements, the enzyme and substrate concentrations could be adjusted to achieve the desired signal-to-noise ratio. In the example in FIG. 4A, it can be seen that this ratio (control versus blank endpoints) was approximately three.
  • FIG. 4A shows that inhibitors A and B completely inhibited Aggrecanase-1 enzyme activity (results are comparable to blank [no enzyme]).
  • Aggrecanase-2 (0.5 to 1 ⁇ g of protein, 17 to 33 picomoles) was diluted in assay buffer (50 mM HEPES pH 7.5, 10 mM CaCl 2 , 0.1M NaCl, 0.05% Brij-35). Samples were prepared containing Inhibitor A, B or C (shown above) at final concentrations ranging from 0.1 to 12.5 ⁇ M (final DMSO concentration of 1.5%). Duplicate assays were run for each concentration of Inhibitor A, B and C (purchased from Peptides International, TAPI-0, Cat. No. INH 3850-P1) for 60 minutes at room temperature.
  • assay buffer 50 mM HEPES pH 7.5, 10 mM CaCl 2 , 0.1M NaCl, 0.05% Brij-35. Samples were prepared containing Inhibitor A, B or C (shown above) at final concentrations ranging from 0.1 to 12.5 ⁇ M (final DMSO concentration of 1.5%).
  • the reaction was initiated by the addition of FasL1 peptide substrate to a final concentration of 225 ⁇ M.
  • the reaction rate data in FIG. 4B were fitted by non-linear regression using the program Grafit (Erithacus Software).
  • the IC50s for inhibition of Aggrecanase-2 by Inhibitors A, B and C, were 118 ⁇ 5, 38 ⁇ 8, and 102 ⁇ 23 nM, respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Separation, Recovery Or Treatment Of Waste Materials Containing Plastics (AREA)
US10/050,200 2002-01-16 2002-01-16 Aggrecanase-1 and -2 peptide substrates and methods Abandoned US20030166037A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US10/050,200 US20030166037A1 (en) 2002-01-16 2002-01-16 Aggrecanase-1 and -2 peptide substrates and methods
AU2003203028A AU2003203028A1 (en) 2002-01-16 2003-01-15 Aggrecanase-1 and -2 peptide substrates and methods
DE60331414T DE60331414D1 (de) 2002-01-16 2003-01-15 Aggrecanase-1- und -2-peptidsubstrate und verfahren
AT03702145T ATE458810T1 (de) 2002-01-16 2003-01-15 Aggrecanase-1- und -2-peptidsubstrate und verfahren
CA2473513A CA2473513C (fr) 2002-01-16 2003-01-15 Substrats peptidiques aggrecanase-1 et -2 et procedes associes
PCT/US2003/001327 WO2003062263A2 (fr) 2002-01-16 2003-01-15 Substrats peptidiques aggrecanase-1 et -2 et procedes associes
EP03702145A EP1474509B1 (fr) 2002-01-16 2003-01-15 Substrats peptidiques aggrecanase-1 et -2 et procedes associes
ES03702145T ES2339758T3 (es) 2002-01-16 2003-01-15 Sustratos peptidicos de agrecanasa-1 y -2 y metodos asociados.
US11/012,797 US7312045B2 (en) 2002-01-16 2004-12-15 Aggrecanase-1 and -2 peptide substrates and methods

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/050,200 US20030166037A1 (en) 2002-01-16 2002-01-16 Aggrecanase-1 and -2 peptide substrates and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/012,797 Continuation US7312045B2 (en) 2002-01-16 2004-12-15 Aggrecanase-1 and -2 peptide substrates and methods

Publications (1)

Publication Number Publication Date
US20030166037A1 true US20030166037A1 (en) 2003-09-04

Family

ID=27609064

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/050,200 Abandoned US20030166037A1 (en) 2002-01-16 2002-01-16 Aggrecanase-1 and -2 peptide substrates and methods
US11/012,797 Expired - Fee Related US7312045B2 (en) 2002-01-16 2004-12-15 Aggrecanase-1 and -2 peptide substrates and methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/012,797 Expired - Fee Related US7312045B2 (en) 2002-01-16 2004-12-15 Aggrecanase-1 and -2 peptide substrates and methods

Country Status (8)

Country Link
US (2) US20030166037A1 (fr)
EP (1) EP1474509B1 (fr)
AT (1) ATE458810T1 (fr)
AU (1) AU2003203028A1 (fr)
CA (1) CA2473513C (fr)
DE (1) DE60331414D1 (fr)
ES (1) ES2339758T3 (fr)
WO (1) WO2003062263A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050164947A1 (en) * 2002-05-01 2005-07-28 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005516614A (ja) 2002-02-05 2005-06-09 ワイス 切断アグレカナーゼ分子
CN101501210A (zh) * 2006-06-09 2009-08-05 苏州圣诺生物医药技术有限公司 分离hiv-1蛋白酶抑制剂的体系和药物组合物
EP2746402A1 (fr) * 2013-03-12 2014-06-25 Academisch Medisch Centrum Procédé de pronostic de la maladie d'Alzheimer et substrats pour utilisation associée
US20200055918A1 (en) * 2017-02-22 2020-02-20 Université de Montréal Novel minor histocompatibility antigens and uses thereof
JP7369428B2 (ja) * 2019-08-09 2023-10-26 国立大学法人群馬大学 糖化合物及びその利用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981200A (en) * 1996-01-31 1999-11-09 The Regents Of The University Of California Tandem fluorescent protein constructs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8513098A (en) * 1998-07-24 2000-02-14 Du Pont Pharmaceuticals Company Assays and peptide substrate for determining aggrecan degrading metallo proteaseactivity
JP2004531456A (ja) * 2000-09-06 2004-10-14 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換ピラゾールを用いてアレルギーを治療する方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981200A (en) * 1996-01-31 1999-11-09 The Regents Of The University Of California Tandem fluorescent protein constructs

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050164947A1 (en) * 2002-05-01 2005-07-28 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
US20050209160A1 (en) * 2002-05-01 2005-09-22 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
US7235526B2 (en) * 2002-05-01 2007-06-26 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
US20080262199A1 (en) * 2002-05-01 2008-10-23 The Board Of Trustees Of Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
US7803775B2 (en) 2002-05-01 2010-09-28 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
US20110009331A1 (en) * 2002-05-01 2011-01-13 Daria Mochly-Rosen Protein kinase c peptides for use in withdrawal
US8507440B2 (en) 2002-05-01 2013-08-13 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal

Also Published As

Publication number Publication date
AU2003203028A1 (en) 2003-09-02
CA2473513C (fr) 2012-03-20
WO2003062263A2 (fr) 2003-07-31
ES2339758T3 (es) 2010-05-25
CA2473513A1 (fr) 2003-07-31
EP1474509A2 (fr) 2004-11-10
ATE458810T1 (de) 2010-03-15
US20050164319A1 (en) 2005-07-28
US7312045B2 (en) 2007-12-25
EP1474509A4 (fr) 2005-12-28
DE60331414D1 (de) 2010-04-08
EP1474509B1 (fr) 2010-02-24
WO2003062263A3 (fr) 2004-01-15

Similar Documents

Publication Publication Date Title
Becker et al. Differences in the Activation Mechanism between the α and β Subunits of Human Meprin.
Debela et al. Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences
Várallyay et al. Two mutations in rat trypsin confer resistance against autolysis
Ljusberg et al. Proteolytic excision of a repressive loop domain in tartrate-resistant acid phosphatase by cathepsin K in osteoclasts
Stennicke et al. Caspases: preparation and characterization
Kuno et al. ADAMTS-1 is an active metalloproteinase associated with the extracellular matrix
Marchenko et al. The structure and regulation of the human and mouse matrix metalloproteinase-21 gene and protein
Bergmann et al. Autolytic activation of recombinant human 72 kilodalton type IV collagenase
JP2000503533A (ja) 蛍光消光基質を用いたタンパク質分解酵素のアッセイ方法
US7312045B2 (en) Aggrecanase-1 and -2 peptide substrates and methods
Denault et al. Ectodomain shedding of furin: kinetics and role of the cysteine‐rich region
CA2534629A1 (fr) Proteases du genie genetique pour purification par affinite et traitement des proteines de fusion
EP1629087A2 (fr) Enzyme a deprotection n-carbobenzyloxy (n-cbz) et utilisations
Kang et al. Autolytic processing at Glu586-Ser587within the cysteine-rich domain of human adamalysin 19/disintegrin-metalloproteinase 19 is necessary for its proteolytic activity
CA2447040C (fr) Epreuves, methodes et moyens
AU2001269750B2 (en) Metalloprotease peptide substrates and methods
McALEESE et al. Sheep mast-cell proteinases-1 and-3: cDNA cloning, primary structure and molecular modelling of the enzymes and further studies on substrate specificity
AU2001269750A1 (en) Metalloprotease peptide substrates and methods
Matsui et al. Cloning and characterization of mouse Klk27, a novel tissue kallikrein expressed in testicular Leydig cells and exhibiting chymotrypsin‐like specificity
JP4708326B2 (ja) タンパク質分解酵素の検出のための改善された方法
Hörber et al. Truncation of the amino-terminus of the recombinant aggrecan rAgg1mut leads to reduced cleavage at the aggrecanase site.: Efficient aggrecanase catabolism may depend on multiple substrate interactions
Fernández-Montalván et al. Electrostatic interactions of domain III stabilize the inactive conformation of μ-calpain
WO2005071100A2 (fr) Procede de determination des activites de modifications et de demodifications de proteines et materiaux appropries associes
Basak et al. In vitro assay for protease activity of proprotein convertase subtilisin kexins (PCSKs): an overall review of existing and new methodologies
JP2004503247A (ja) 新規モータータンパク質およびその使用方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: ORTHO-MCNEIL PHARMACEUTICAL, INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FOURIE, ANNE;KARLSSON, LARS;COLES, FAWN;REEL/FRAME:012731/0230

Effective date: 20020419

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION